<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">3994907</article-id>
      <article-id pub-id-type="pmc">1977054</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Placental alkaline phosphatase as a tumour marker in seminoma using the H17 E2 monoclonal antibody assay.</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Horwich</surname>
            <given-names>A.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tucker</surname>
            <given-names>D. F.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Peckham</surname>
            <given-names>M. J.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>1985</year>
      </pub-date>
      <volume>51</volume>
      <issue>5</issue>
      <fpage>625</fpage>
      <lpage>629</lpage>
      <abstract>
        <p>Serum samples from 62 patients with seminoma were assayed for placental alkaline phosphatase-like activity using the monoclonal antibody H17 E2, in order to evaluate its utility as a serum tumour marker. Fifteen of 16 patients (94%) with active seminoma had elevated serum PLAP levels. Sixteen of 46 (35%) of patients considered to be in remission had elevated PLAP levels (false positive rate 35%). Fifteen false positive results were considered attributable to concomitant smoking, and if these patients are excluded, only one false positive case was detected. In 7 out of 7 patients sequential PLAP assays reflected clinical response to treatment.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <supplementary-material content-type="scanned-pages">
      <graphic xlink:href="brjcancer00103-0002.tif" xlink:title="scanned-page" xlink:role="625" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00103-0003.tif" xlink:title="scanned-page" xlink:role="626" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00103-0004.tif" xlink:title="scanned-page" xlink:role="627" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00103-0005.tif" xlink:title="scanned-page" xlink:role="628" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00103-0006.tif" xlink:title="scanned-page" xlink:role="629" mimetype="image" mime-subtype="tiff"/>
    </supplementary-material>
  </body>
</article>
</pmc-articleset>
